Soleno Therapeutics Investor Relations Material
Latest events
FDA Announcement
Soleno Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Soleno Therapeutics Inc
Access all reports
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of rare diseases. The company's primary focus is on Prader-Willi Syndrome (PWS), a genetic disorder characterized by chronic hunger, behavioral problems, and other severe health issues. Soleno's lead product candidate, Diazoxide Choline Extended-Release (DCCR) tablets, is currently undergoing evaluation in a Phase III clinical trial as a potential treatment for PWS. This once-daily oral medication aims to address the disorder's hallmark symptoms and improve patient outcomes. The company is headquartered in Redwood City, California, and its shares are listed on NASDAQ.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
SLNO
Country
🇺🇸 United States